UCB - Dusseldorf Stock Exchang (UNC DU) stock market data APIs
€161.7017
0(0%)
as of July 4, 2025
Try our APIs with
free plan!
UCB - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for UNC.DU.
Prev. Close
161.7017
Open
161.7017
High
161.7017
Low
161.7017
52 wk Range
134.3572-195.9149
Market Cap
18 821 M
Dividends (Yield)
0.015
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get UCB - Dusseldorf Stock Exchang data using free add-ons & libraries
Get UCB - Dusseldorf Stock Exchang Fundamental Data
UCB - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
UCB - Dusseldorf Stock Exchang News
New
UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
Phase 3 study met primary and most key secondary clinical endpoints This marks the third developmental and epileptic encephalopathies (DEE) population for fenfluramine with positive phase 3 results R...
UCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference
UCB will contribute three presentations, including data on the disease course of thymidine kinase 2 deficiency (TK2d) in untreated patients and insights into caregiver impact These data emphasize UCB...
Inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S.
ATLANTA, June 17, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that 15 scholarships were awarded to people impacted by myasthenia gravis in the U.S. The UCB Myastheni...
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
Committed to serve U.S. patients and deliver economic impact of approximately $5 billion, including creation of 300 U.S. direct high skilled jobs and more than 500 construction jobs Scaling up U.S. ba...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
